CEO Fired

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Rate Cut Hopes

Rate Cut Hopes

BarCap expects bigger rate cuts in India in 2013.  Full Article 

Rupee Low

Rupee Low

Rupee hits 2013 low on importer demand, weak euro  Full Article | Related Story 

Vodafone Result

Vodafone Result

Vodafone keeps Verizon payout to make up for European slump  Full Article 

Tumble Bought

Tumble Bought

Yahoo's rise in Asia offsets risk from Tumblr bet  Full Article 

Bond Business

Bond Business

RBI says foreign investors may buy inflation-linked bonds  Full Article | Related Story 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-India's Maruti Suzuki rallies on sales hopes

Related Topics

Stocks

   
Visitors look at a display of flowers during media day at the Chelsea Flower Show in London May 20, 2013. REUTERS/Stefan Wermuth

Chelsea Flower Show

The Queen, Prince Harry as well as garden gnomes turn up at the 100th annual Chelsea Flower Show.  Slideshow 

Mon Nov 19, 2012 12:11pm IST

* Shares in Maruti Suzuki and Mahindra & Mahindra
 gain on hopes for rising sales this month as part of
the festival season.
* Indian brokerage Sharekhan said both Maruti and Mahindra &
Mahindra will outperform the sector in the near-term, citing a
"strong" order backlog, according to an email to clients.
* Six models from the two companies, including the Maruti Dzire
and the Mahindra XUV 500, have pending orders of about 170,000
units, or as much as 75 percent of the average monthly passenger
vehicle sales recorded in the broader sector, as per Sharekhan
calculations.
* A weakening Japanese yen is also helping Maruti Suzuki
shares given expectations it will reduce the cost of royalty
payments to Suzuki Motor. 
* Maruti shares gain 4.2 percent, while Mahindra & Mahindra
shares gain 1.5 percent.

 (manoj.dharra@thomsonreuters.com)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.